Exhausted T cell signature predicts immunotherapy response in ER-positive breast cancer

Exhausted T cell signature predicts immunotherapy response in ER-positive breast cancer

ER-positive breast cancer patients do not usually respond to immunotherapy. In this phase II clinical trial, the authors report the safety and efficacy of combining vorinostat and pembrolizumab with tamoxifen in ER-positive breast cancers and provide evidence that T-cell exhaustion may serve as a po...

Full description

Saved in:
Bibliographic Details
Main Authors: Manuela Terranova-Barberio, Nela Pawlowska, Mallika Dhawan, Mark Moasser, Amy J. Chien, Michelle E. Melisko, Hope Rugo, Roshun Rahimi, Travis Deal, Adil Daud, Michael D. Rosenblum, Scott Thomas, Pamela N. Munster
Format: article
Language:EN
Published: Nature Portfolio 2020
Subjects:
Science
Q
Online Access:https://doaj.org/article/64f0fec706954f5c93dba4c047a3944a
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doaj.org/article/64f0fec706954f5c93dba4c047a3944a

Similar Items